Tevogen Bio (TVGN) Competitors $1.03 +0.02 (+1.98%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVGN vs. REPL, NUVB, CRON, PAHC, AVBP, LENZ, EOLS, DNTH, ANAB, and XERSShould you be buying Tevogen Bio stock or one of its competitors? The main competitors of Tevogen Bio include Replimune Group (REPL), Nuvation Bio (NUVB), Cronos Group (CRON), Phibro Animal Health (PAHC), ArriVent BioPharma (AVBP), LENZ Therapeutics (LENZ), Evolus (EOLS), Dianthus Therapeutics (DNTH), AnaptysBio (ANAB), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry. Tevogen Bio vs. Replimune Group Nuvation Bio Cronos Group Phibro Animal Health ArriVent BioPharma LENZ Therapeutics Evolus Dianthus Therapeutics AnaptysBio Xeris Biopharma Replimune Group (NASDAQ:REPL) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership. Does the MarketBeat Community believe in REPL or TVGN? Replimune Group received 164 more outperform votes than Tevogen Bio when rated by MarketBeat users. However, 100.00% of users gave Tevogen Bio an outperform vote while only 64.02% of users gave Replimune Group an outperform vote. CompanyUnderperformOutperformReplimune GroupOutperform Votes16964.02% Underperform Votes9535.98% Tevogen BioOutperform Votes5100.00% Underperform VotesNo Votes Is REPL or TVGN more profitable? Replimune Group's return on equity of -54.84% beat Tevogen Bio's return on equity.Company Net Margins Return on Equity Return on Assets Replimune GroupN/A -54.84% -42.97% Tevogen Bio N/A -396.07%749.97% Which has more volatility and risk, REPL or TVGN? Replimune Group has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Tevogen Bio has a beta of -0.84, meaning that its share price is 184% less volatile than the S&P 500. Which has higher valuation and earnings, REPL or TVGN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReplimune GroupN/AN/A-$215.79M-$3.07-3.03Tevogen BioN/AN/A-$70KN/AN/A Do insiders and institutionals hold more shares of REPL or TVGN? 92.5% of Replimune Group shares are owned by institutional investors. 8.8% of Replimune Group shares are owned by company insiders. Comparatively, 56.6% of Tevogen Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts recommend REPL or TVGN? Replimune Group currently has a consensus price target of $19.43, suggesting a potential upside of 108.91%. Tevogen Bio has a consensus price target of $7.10, suggesting a potential upside of 603.67%. Given Tevogen Bio's higher possible upside, analysts plainly believe Tevogen Bio is more favorable than Replimune Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Replimune Group 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Tevogen Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to REPL or TVGN? In the previous week, Replimune Group and Replimune Group both had 9 articles in the media. Replimune Group's average media sentiment score of 1.39 beat Tevogen Bio's score of 0.28 indicating that Replimune Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 5 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tevogen Bio 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryReplimune Group beats Tevogen Bio on 8 of the 13 factors compared between the two stocks. Get Tevogen Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TVGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVGN vs. The Competition Export to ExcelMetricTevogen BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$185.55M$2.97B$5.53B$7.73BDividend YieldN/A1.89%5.11%4.22%P/E RatioN/A30.3022.4418.38Price / SalesN/A494.12390.71103.40Price / CashN/A168.6838.1834.62Price / Book-0.923.186.704.22Net Income-$70,000.00-$72.35M$3.22B$248.14M7 Day Performance-1.08%1.64%2.23%2.49%1 Month Performance-15.92%-1.68%-0.93%1.01%1 Year Performance0.90%-21.97%17.52%4.98% Tevogen Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVGNTevogen Bio3.0955 of 5 stars$1.03+2.0%$7.10+589.3%+1.0%$189.41MN/A0.003Analyst ForecastNews CoverageREPLReplimune Group4.1737 of 5 stars$8.77+9.8%$19.43+121.5%+42.7%$675.42MN/A-2.86210Positive NewsNUVBNuvation Bio3.5987 of 5 stars$1.99+0.8%$8.75+340.8%-26.1%$672.28M$7.87M-0.9160Upcoming EarningsCRONCronos Group1.5122 of 5 stars$1.74-1.7%$3.50+101.1%-27.5%$670.61M$117.62M-13.38450PAHCPhibro Animal Health3.3388 of 5 stars$16.53-4.4%$19.75+19.5%+12.5%$669.52M$1.11B34.441,860Upcoming EarningsPositive NewsAVBPArriVent BioPharma1.0033 of 5 stars$19.54+7.7%$39.00+99.6%+27.9%$664.67MN/A-7.6040Short Interest ↑Positive NewsLENZLENZ Therapeutics1.8631 of 5 stars$24.11+1.2%$46.60+93.3%+61.4%$664.06MN/A-5.05110Positive NewsEOLSEvolus3.8685 of 5 stars$10.38-3.8%$23.75+128.8%-1.2%$660.03M$266.27M-11.41170Upcoming EarningsNews CoveragePositive NewsDNTHDianthus Therapeutics1.6053 of 5 stars$20.45+4.9%$54.33+165.7%-0.7%$656.98M$6.24M-8.1880News CoveragePositive NewsANABAnaptysBio2.4497 of 5 stars$20.62+0.3%$33.63+63.1%-0.6%$632.35M$91.28M-3.39100Positive NewsXERSXeris Biopharma3.5853 of 5 stars$4.02-2.2%$6.10+51.7%+152.0%$618.84M$203.07M-8.93290 Related Companies and Tools Related Companies Replimune Group Competitors Nuvation Bio Competitors Cronos Group Competitors Phibro Animal Health Competitors ArriVent BioPharma Competitors LENZ Therapeutics Competitors Evolus Competitors Dianthus Therapeutics Competitors AnaptysBio Competitors Xeris Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVGN) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersTop performing AI play of the decade…? (The answer will shock you)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tevogen Bio Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tevogen Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TVGN Stock Free TVGN Stock Alerts